GlassScriptPhysician profile
Elizabeth Anne Embry
NPI 1902474612
$3,380.44
in general payments reported to CMS, 2019-2025
27 companies · $685 in 2025
The $685 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $1,190 · 2023: $617 · 2024: $592 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803 · Education: $90.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.37 |
| Education | $90.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $664.08 | 2022-2024 | Ova1 |
| Abbvie INC. | $550.30 | 2021-2025 | |
| Biogen, INC. | $431.25 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $230.57 | 2021-2025 | |
| Astellas Pharma US INC | $203.39 | 2022-2025 | Veozah |
| Shield Therapeutics INC | $166.06 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $132.48 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $126.22 | 2021-2023 | Wegovy, Saxenda |
| Organon LLC | $121.99 | 2022-2025 | Nexplanon |
| Biohaven Pharmaceutical Holding Company LTD. | $87.92 | 2022 | |
| Daiichi Sankyo INC. | $82.33 | 2021-2024 | Injectafer |
| Myovant Sciences INC. | $73.93 | 2022 | |
| Exeltis, USA INC. | $65.07 | 2022-2025 | Slynd |
| Millicent US INC | $54.73 | 2023-2025 | Intrarosa, Femring |
| Pfizer INC. | $52.95 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.50 | 2022-2024 | Prolia, Evenity |
| Laborie Medical Technologies Corp. | $39.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.35 | 2021-2025 | |
| Baxter Healthcare | $35.74 | 2024 | Perclot |
| Channel Medsystems, INC. | $34.12 | 2023 | |
| Axonics, INC. | $32.53 | 2021 | |
| Hologic Sales and Service, LLC | $30.78 | 2022-2025 | Aptima |
| Agile Therapeutics, INC. | $19.34 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.37 | 2021 | |
| Exact Sciences Corporation | $16.95 | 2023 | Cologuard Collection Kit |
| Radius Health, INC. | $14.03 | 2025 | Tymlos |
| Ipsen Biopharmaceuticals, INC | $13.46 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Embry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.